Clustering data with hclust algorithm for (Study ST002125)
(Analysis AN003478)| Metabolite | Structure | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 | F13 | F14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [13C]Fumatate | ME516688 | NA | NA | 4.39 | 0.01 | 0.01 | 0.01 | 4.60 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 2.90 |
| [13C]Alpha_Ketoglutarate | ME516686 | NA | NA | 4.46 | 0.01 | 0.01 | 0.01 | 4.43 | 0.01 | 0.01 | 0.01 | 0.02 | 0.05 | 0.03 | 2.93 |
| [13C]Succinate | ME516690 | NA | NA | 4.50 | 0.01 | 0.01 | 0.01 | 4.49 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 2.91 |
| [13C]Citrate | ME516687 | NA | NA | 4.44 | 0.01 | 0.01 | 0.01 | 4.93 | 0.01 | 0.01 | 0.01 | 0.02 | 0.06 | 0.04 | 2.45 |
| [13C]Malate | ME516689 | NA | NA | 4.76 | 0.01 | 0.02 | 0.02 | 4.92 | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 | 0.02 | 2.18 |
| [13C, 15N]Glutamic acid, 3TBDMS | ME516673 | NA | NA | 0.03 | 2.87 | 0.90 | 1.53 | 0.03 | 2.37 | 0.67 | 1.26 | 1.09 | 0.22 | 0.64 | 0.01 |
| [13C, 15N]Alanine, 2TBDMS | ME516671 | NA | NA | 0.01 | 1.49 | 1.36 | 1.23 | 0.01 | 1.41 | 1.36 | 1.23 | 1.47 | 1.09 | 1.27 | 0.01 |
| [13C, 15N]Leucine, 2TBDMS | ME516677 | NA | NA | 0.02 | 2.15 | 0.93 | 1.49 | 0.02 | 2.11 | 0.84 | 1.48 | 1.36 | 0.47 | 0.90 | 0.01 |
| [13C, 15N]Tyrosine, 3TBDMS | ME516684 | NA | NA | 0.02 | 2.14 | 1.02 | 1.59 | 0.02 | 2.01 | 0.82 | 1.56 | 1.25 | 0.56 | 0.84 | 0.01 |
| [13C, 15N]Proline, 2TBDMS | ME516681 | NA | NA | 0.02 | 1.92 | 1.18 | 1.54 | 0.02 | 2.12 | 1.08 | 1.70 | 1.13 | 0.36 | 0.78 | 0.01 |
| [13C, 15N]Isoleucine, 2TBDMS | ME516676 | NA | NA | 0.02 | 1.90 | 1.16 | 1.62 | 0.02 | 1.79 | 1.40 | 1.61 | 1.27 | 0.40 | 0.74 | 0.01 |
| [13C, 15N]Histidine, 3TBDMS | ME516675 | NA | NA | 0.02 | 1.87 | 1.37 | 1.58 | 0.02 | 1.77 | 1.25 | 1.49 | 1.27 | 0.37 | 0.88 | 0.02 |
| [13C, 15N]Valine, 2TBDMS | ME516685 | NA | NA | 0.00 | 1.84 | 1.26 | 1.59 | 0.00 | 1.87 | 1.15 | 1.53 | 1.35 | 0.46 | 0.83 | 0.00 |
| [13C, 15N]Aspartic acid, 3TBDMS | ME516672 | NA | NA | 0.02 | 2.20 | 0.90 | 1.21 | 0.02 | 1.96 | 0.87 | 1.04 | 1.74 | 0.67 | 1.06 | 0.02 |
| [13C, 15N]Methionine, 2TBDMS | ME516679 | NA | NA | 0.02 | 1.92 | 1.29 | 1.54 | 0.02 | 1.64 | 1.16 | 1.32 | 1.33 | 0.75 | 0.90 | 0.01 |
| [13C, 15N]Glycine, 2TBDMS | ME516674 | NA | NA | 0.02 | 1.77 | 1.13 | 1.38 | 0.02 | 1.73 | 1.22 | 1.30 | 1.48 | 0.74 | 1.06 | 0.02 |
| [13C, 15N]Serine, 3TBDMS | ME516682 | NA | NA | 0.02 | 1.76 | 1.10 | 1.39 | 0.02 | 1.81 | 1.07 | 1.48 | 1.27 | 0.90 | 1.07 | 0.01 |
| [13C, 15N]Lysine, 3TBDMS | ME516678 | NA | NA | 0.02 | 1.90 | 0.93 | 1.33 | 0.02 | 1.83 | 0.93 | 1.19 | 1.57 | 0.77 | 1.29 | 0.01 |
| [13C, 15N]Phenylalanine, 2TBDMS | ME516680 | NA | NA | 0.02 | 1.84 | 0.87 | 1.34 | 0.02 | 1.75 | 0.97 | 1.50 | 1.78 | 0.68 | 1.13 | 0.02 |
| [13C, 15N]Threonine, 3TBDMS | ME516683 | NA | NA | 0.02 | 1.73 | 1.00 | 1.38 | 0.02 | 1.70 | 1.07 | 1.49 | 1.64 | 0.79 | 1.08 | 0.01 |
Factors:
| F1 | Source_Name[gating]:Bone marrow supernatant | Treatment:5 FU 2 weeks | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D) |
| F2 | Source_Name[gating]:Bone marrow supernatant | Treatment:HSC Basal | Batch:1c | Note:Unlabeled AAs were used for total AA (FigS2.D) |
| F3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). |
| F4 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). |
| F5 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). |
| F6 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). |
| F7 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C) and TCA substrate levels (Fig2.K). |
| F8 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). |
| F9 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). |
| F10 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:Ex vivo culture 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig2.D). |
| F11 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). |
| F12 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). |
| F13 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). |
| F14 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). |
